- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Chemomab Therapeutics Ltd DRC (CMMB)Chemomab Therapeutics Ltd DRC stock price live, this page displays NASDAQ CMMB stock exchange data. View the CMMB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Chemomab Therapeutics Ltd DRC real time stock price chart below.
What Is the Chemomab Therapeutics Ltd DRC Stock Price Today?
The Chemomab Therapeutics Ltd DRC stock price today is 1.6700.
What Is the Stock Symbol for Chemomab Therapeutics Ltd DRC?
The stock symbol for Chemomab Therapeutics Ltd DRC is "CMMB."
What Stock Exchange Does Chemomab Therapeutics Ltd DRC Trade On?
Chemomab Therapeutics Ltd DRC is listed and trades on the NASDAQ stock exchange.
Is Chemomab Therapeutics Ltd DRC a Good Stock to Buy?
Determining whether Chemomab Therapeutics Ltd DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CMMB quote. (ISIN: US16385C1045)
What Is the Chemomab Therapeutics Ltd DRC Stock Price Today?
The Chemomab Therapeutics Ltd DRC stock price today is 1.6700.
What Is the Stock Symbol for Chemomab Therapeutics Ltd DRC?
The stock symbol for Chemomab Therapeutics Ltd DRC is "CMMB."
What Stock Exchange Does Chemomab Therapeutics Ltd DRC Trade On?
Chemomab Therapeutics Ltd DRC is listed and trades on the NASDAQ stock exchange.
Is Chemomab Therapeutics Ltd DRC a Good Stock to Buy?
Determining whether Chemomab Therapeutics Ltd DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CMMB quote. (ISIN: US16385C1045)
NASDAQ
Currency in USD
1.6700
-0.0600(-3.47%)
Closed
After Hours
1.6500-0.0200(-1.1976%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.6100
1.7700
52 wk Range
0.4200
2.5500
CMMB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.61001.7700
52 wk Range
0.42002.5500
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockCMMB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
8.0000
Upside
+379.0419%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Chemomab reports progress in PSC treatment trial
- Investing.com
- Chemomab reports progress in PSC treatment trial
- Investing.com
Chemomab Therapeutics Ltd DRC Company Profile
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Compare CMMB to Peers and Sector
Metrics to compare | CMMB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCMMBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −2.4x | −0.7x | |
PEG Ratio | −0.04 | −0.05 | 0.00 | |
Price/Book | 1.9x | 1.9x | 2.6x | |
Price / LTM Sales | - | 361.3x | 3.2x | |
Upside (Analyst Target) | - | 431.0% | 45.9% | |
Fair Value Upside | Unlock | 4.1% | 7.6% | Unlock |
Analysts' Recommendations
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 8.0000
(+379.04% Upside)
People Also Watch
FAQ
What Is the Chemomab Therapeutics DRC (CMMB) Stock Price Today?
The Chemomab Therapeutics DRC stock price today is 1.67
What Stock Exchange Does Chemomab Therapeutics DRC Trade On?
Chemomab Therapeutics DRC is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Chemomab Therapeutics DRC?
The stock symbol for Chemomab Therapeutics DRC is "CMMB."
What Is the Chemomab Therapeutics DRC Market Cap?
As of today, Chemomab Therapeutics DRC market cap is 31.49M.
What is Chemomab Therapeutics DRC Earnings Per Share?
The Chemomab Therapeutics DRC EPS is -0.975.
What Is the Next Chemomab Therapeutics DRC Earnings Date?
Chemomab Therapeutics DRC will release its next earnings report on 05 Mar 2025.
From a Technical Analysis Perspective, Is CMMB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.